• Secured FDA CLIA waiver for Lumos' FebriDx, unlocking significant growth in the US market for Pascal supply
• Received over $2 million in new orders during the quarter
• Expanding test portfolio with development of novel Syphilis and Liver Function tests

Atomo Diagnostics Limited, an innovative diagnostics company, has reported its Q3 FY26 results. Key highlights include:- The company secured FDA CLIA waiver approval for Lumos' FebriDx test, which unlocks significant growth in the US market for Pascal supply. This also provides a predicate pathway to the US market for Atomo's own diagnostic test products and validates a valuable market expansion opportunity via Pascal for new customers.- Atomo received over $2 million in new orders during the quarter, including a large HIV order from NAPWHA in Australia and New Zealand, as well as additional orders for its Pascal cassettes.- The company is expanding its test portfolio, with the development of a novel Syphilis test that can distinguish active and prior treated Syphilis, as well as a Liver Function test for the diagnosis and monitoring of liver damage associated with various chronic diseases.- Atomo's cash position remained strong at $2.6 million at the end of the quarter, with the company remaining debt-free. Operating expenses were well-managed and deployed towards strategic growth opportunities.- The company continues to see strong momentum in its established revenue channels, including HIV tests and Pascal cassettes, and is targeting further growth in FY26.

Atomo is targeting strong growth in FY26 as it expands its test portfolio and customer base, leveraging the CLIA waiver approval for Lumos' FebriDx to drive increased demand for its Pascal cassettes. The company is also progressing the development and commercialization of its novel Syphilis and Liver Function tests.